Sebastian Walpen
Overview
Explore the profile of Sebastian Walpen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sukul N, Zhao J, Pisoni R, Walpen S, Schaufler T, Asgari E, et al.
Am J Kidney Dis
. 2023 Oct;
82(6):666-676.
PMID: 37777951
Rationale & Objective: Cross-sectional studies have reported an association of chronic kidney disease-associated pruritus (CKD-aP) with adverse clinical events and patient-reported outcomes (PROs). We studied the longitudinal associations between changes...
2.
Liu J, Zuo L, Walpen S, Bernard L, Marty M, Enoiu M
Nephron
. 2023 Jul;
148(1):22-33.
PMID: 37473746
Introduction: This study aimed to investigate the efficacy and safety of sucroferric oxyhydroxide (SFOH) versus sevelamer carbonate in controlling serum phosphorus (sP) in adult Chinese dialysis patients with hyperphosphataemia (sP...
3.
Burton J, Walpen S, Danel S, Schroppel B
Kidney Int Rep
. 2023 Jul;
8(7):1455-1459.
PMID: 37441482
No abstract available.
4.
Weiner D, Vervloet M, Walpen S, Schaufler T, Munera C, Menzaghi F, et al.
Kidney Med
. 2022 Oct;
4(10):100542.
PMID: 36185706
Rationale & Objective: Individuals with chronic kidney disease frequently suffer from chronic kidney disease-associated pruritus (CKD-aP), impacting sleep quality and quality of life (QoL) and increasing the likelihood of depression....
5.
Barreto Lopes M, Karaboyas A, Sukul N, Tsuruya K, Al Salmi I, Asgari E, et al.
Kidney Med
. 2022 Jun;
4(6):100476.
PMID: 35651592
Rationale & Objective: Chronic kidney disease-associated pruritus has been linked with poorer mental and physical health-related quality of life (HR-QOL) in patients receiving hemodialysis. We used the Skindex-10 questionnaire and...
6.
Herrero J, Salomone M, Ramirez de Arellano A, Schaufler T, Walpen S
J Med Econ
. 2021 Nov;
24(1):1240-1247.
PMID: 34761724
Aims: Hyperphosphatemia is common among patients with advanced chronic kidney disease (CKD) undergoing dialysis. The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SO), has a low daily pill burden and is...
7.
McCullough K, Port F, de Sequera P, Rayner H, Pecoits-Filho R, Walpen S, et al.
Clin Kidney J
. 2021 Aug;
14(8):1886-1893.
PMID: 34345411
Background: Hemodialysis (HD) patients are commonly prescribed phosphate binders (PBs) to manage serum phosphorus levels, as hyperphosphatemia is strongly associated with poorer survival. Nonadherence with the PB prescription is associated...
8.
Vervloet M, Boletis I, de Francisco A, Kalra P, Ketteler M, Messa P, et al.
Clin Kidney J
. 2021 Jul;
14(7):1770-1779.
PMID: 34221384
Background: The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), is indicated to control serum phosphorus levels in patients with chronic kidney disease on dialysis. Methods: This non-interventional, prospective, multicentre, cohort...
9.
Ramos R, Chazot C, Ferreira A, Di Benedetto A, Gurevich K, Feuersenger A, et al.
BMC Nephrol
. 2020 Dec;
21(1):530.
PMID: 33287733
Background: The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), demonstrated its effectiveness for lowering serum phosphate levels, with low daily pill burden, in clinical trials of dialysis patients with hyperphosphatemia....
10.
Neven E, Corremans R, Vervaet B, Funk F, Walpen S, Behets G, et al.
Nephrol Dial Transplant
. 2020 Oct;
35(10):1689-1699.
PMID: 33022710
Introduction: Sucroferric oxyhydroxide (PA21) is an efficacious, well-tolerated iron-based phosphate binder and a promising alternative to existing compounds. We compared the effects of PA21 with those of a conventional phosphate...